Complement Therapeutics complementtx.com/

Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotech focused on the research and development of novel therapeutics for complement-mediated diseases. CTx is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
CTx lead investigational product (CTx001) is being evaluated as a potential gene therapy for Geographic Atrophy, a leading cause of blindness.